Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NOV-002 · NSC-755883

Small molecule · Modulator of gamma-glutamyl transpeptidase (GGT1) · developed by Cellectar Biosciences

Phase 3 Most advanced trial (none active)

CLRB Developer

1 Registered trials

What is NOV-002?

NOV-002 is a stabilized formulation of disodium glutathione disulfide (oxidized glutathione) combined with a trace amount of cisplatin. It acts as a competitive substrate for gamma-glutamyl transpeptidase, leading to protein S-glutathionylation, endoplasmic reticulum stress and phosphorylation of ERK and p38. It is studied in non-small cell lung cancer in combination with paclitaxel and carboplatin.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: NSC-755883
Drug type: Small molecule
Targets: gamma-glutamyl transpeptidase (GGT1) (binding partner it blocks)
Mechanism: Modulator of gamma-glutamyl transpeptidase (GGT1)
Pathways: S-glutathionylation of proteins, endoplasmic reticulum stress-induced apoptosis, ERK and p38 phosphorylation
Therapy area: Oncology
Developer: Cellectar Biosciences, Inc. (CLRB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: GY131TX61G

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00347412	Phase 3	Non Small Cell Lung Cancer	Completed	CLRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Small Cell Lung Cancer

More from Cellectar Biosciences

Cyclophosphamate Phase 3 Iodine I 124 Iopofosine Phase 2 Iodine I 125 Iopofosine Phase 1 Iodine I 131 Iopofosine Phase 3 NM404 Phase 1 NOV-205 Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLRB page.

Follow CLRB, the company behind NOV-002

See CLRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLRB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z